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of Creatine Kinase-Myocardial Band Rather
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of Periprocedural Necrosis and Infarction
After Coronary Intervention
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Objectives We aimed to assess the differential implications of creatine kinase-myocardial band (CK-MB) and troponin mea-
surement with the universal definition of periprocedural injury after percutaneous coronary intervention.
Background Differentiation between definitions of periprocedural necrosis and periprocedural infarction has practical, socio-
logical, and research implications. Troponin is the recommended biomarker, but there has been debate about
the recommended diagnostic thresholds.
Methods Thirty-two patients undergoing multivessel percutaneous coronary intervention and late gadolinium enhance-
ment (LGE) cardiac magnetic resonance (CMR) imaging in a prospective study had cardiac troponin I, CK-MB,
and inflammatory markers (C-reactive protein, serum amyloid A, myeloperoxidase, tumor necrosis factor alpha)
measured at baseline, 1 h, 6 h, 12 h, and 24 h after the procedure. Three “periprocedural injury” groups were
defined with the universal definition: G1: no injury (biomarker 99th percentile); G2: periprocedural necrosis
(1 to 3  99th percentile); G3: myocardial infarction (MI) type 4a (3  99th percentile). Differences in inflam-
matory profiles were analyzed.
Results With CK-MB there were 17, 10, and 5 patients in groups 1, 2, and 3, respectively. Patients with CK-MB–defined
MI type 4a closely approximated patients with new CMR-LGE injury. Groups defined with CK-MB showed progres-
sively increasing percentage change in C-reactive protein and serum amyloid A, reflecting increasing inflamma-
tory response (p  0.05). Using cardiac troponin I resulted in 26 patients defined as MI type 4a, but only a small
minority had evidence of abnormality on CMR-LGE, and only 3 patients were defined as necrosis. No differences
in inflammatory response were evident when groups were defined with troponin.
Conclusions Measuring CK-MB is more clinically relevant for diagnosing MI type 4a, when applying the universal definition.
Current troponin thresholds are oversensitive with the arbitrary limit of 3  99th percentile failing to discrimi-
nate between periprocedural necrosis and MI type 4a. (Myocardial Injury following Coronary Artery bypass Sur-
gery versus Angioplasty: a randomised controlled trial using biochemical markers and cardiovascular magnetic
resonance imaging; ISRCTN25699844) (J Am Coll Cardiol 2011;57:653–61) © 2011 by the American College
of Cardiology Foundation
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(PMI) can result from procedural
complications of percutaneous
coronary intervention (PCI),
such as distal embolization, side-
branch occlusion, coronary dis-
section, and disruption of collat-
eral flow (1). In some of these
cases a complication is clinically
evident, but evidence of myocar-
dial injury can also be detected
after routine uneventful PCI pro-
cedures. The increasing sensitivity
of blood biomarkers, particularly
troponin, has reinvigorated debate
about the significance of elevations
in troponin, creatine kinase (CK),
and creatine kinase-myocardial band
(CK-MB) (2–7), but it is clear that
elevation of CK-MB 3 to 8
upper reference limit (URL) has a
prognostic implication especially
if accompanied by the develop-
ment of Q waves on the electro-
cardiogram (8,9). Troponin is a
articularly sensitive biomarker, introduced predominantly
or risk stratification in patients with acute coronary syn-
rome (10). Studies measuring troponin after PCI with
ardiac magnetic resonance (CMR) with late gadolinium
nhancement (LGE), have demonstrated a relationship
etween moderate to high troponin elevations and CMR
vidence of new myocardial necrosis (11,12).
See page 662
Recognizing the need for a universal definition of
periprocedural myocardial infarction (MI), the joint Euro-
pean Society of Cardiology/American College of Cardiol-
ogy Foundation/American Heart Association/World Heart
Federation task force recently established definitions for
myocardial injury after PCI. Periprocedural myocardial
necrosis (PMN) is defined as elevation of cardiac biomark-
ers above the URL of the 99th percentile of the normal
population, assuming normal baseline troponin levels and an
assay coefficient of variation 10% at this limit (13). The
Universal Definition states that troponin is the preferred
biomarker and an elevation of more than 3 the 99th
for Health Research Oxford Biomedical Research Centre Programme, United
Kingdom. Dr. Antoniades is funded by the European Association of Percutaneous
Coronary Interventions. Prof. Neubauer, Dr. Karamitsos, and Dr. Petersen are
partially funded by the Medical Research Council (United Kingdom) and British
Heart Foundation. Dr. Banning has received unrestricted grants from Cordis and
Boston Scientific. All other authors have reported that they have no relationships to
disclose.
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
CMR  cardiac magnetic
resonance imaging
CRP  C-reactive protein
cTnI  cardiac troponin I
LGE  late gadolinium
enhancement
MI  myocardial infarction
MPO  myeloperoxidase
PCI  percutaneous
coronary intervention
PMI  periprocedural
myocardial injury
PMN  periprocedural
myocardial necrosis
SAA  serum amyloid A
TNF  tumor necrosis
factor
URL  upper reference
limitManuscript received May 27, 2010; revised manuscript received June 22, 2010,
accepted July 6, 2010.percentile URL is defined as a PCI-related MI (MI type 4a)
(13). There are currently no data to demonstrate whether
this arbitrary limit in the absolute level of the biomarker
appropriately divides patients with PMN and those with MI
type 4a. Indeed the definition of MI type 4a has been
considered to be too sensitive for reporting in clinical trials
and consequently, investigators have advocated use of the
less-sensitive CK-MB assay instead of troponin when ap-
plying this new definition of MI (14,15).
Percutaneous coronary intervention induces plaque dis-
ruption and local vessel wall trauma that can induce an
inflammatory response measurable by a rise in circulatory
inflammatory cytokines (16–20). Additionally myocyte ne-
crosis will induce a larger inflammatory response, which can
also be measured (21,22).
With data from a prospective randomized trial of com-
plex PCI we aimed to analyze evidence of myocardial injury
between patients with diagnosis of PMN and those with MI
type 4a.
We hypothesized that the current arbitrary definitions
with CK-MB might be superior to troponin in representing
the continuum of periprocedural injury (no injury ¡
PMN ¡ MI type 4a) and measured inflammatory cytokine
profiles and sought anatomic evidence of infarction with
CMR-LGE.
Methods
The MICASA (Myocardial Injury following Coronary
Artery Surgery versus Angioplasty) trial was a prospective,
single-center, randomized (1:1) trial of myocardial injury
after PCI compared with coronary artery bypass grafting.
The primary end point was myocardial injury defined by
troponin and CMR.
The study was approved by the local ethics committee, and
informed written consent was obtained from each patient.
Treatment and procedures. A detailed description of the
study procedures is described elsewhere (23). Briefly, pa-
tients undergoing PCI were pre-treated with aspirin 75 mg
once daily for at least 2 days and clopidogrel 300 mg at least
6 h before PCI. Heparin was given intravenously to all
patients. Upfront glycoprotein IIb/IIIa inhibitor (abcix-
imab) followed by a 12-h infusion and use of drug-eluting
stents were the preferred strategy. All patients underwent
PCI in 1 session. Most bifurcations were managed with a
provisional T strategy.
CMR imaging time points, protocol, post-processing,
and data analysis. Patients were studied at 1.5-T (Sonata,
Siemens Healthcare, Erlangen, Germany). Baseline CMR
assessment was performed in the fortnight before revascular-
ization. Repeat CMR was performed 7 days (range 4 to
10 days) after the revascularization. The LGE imaging was
performed as previously described (11,12). For analysis of
LGE, 2 experienced observers who were blinded to patient
data interpreted the images. When measurements were differ-
ent, review was performed by a third observer and a consensus
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February 8, 2011:653–61 Biomarkers and Periprocedural Necrosiswas obtained. Areas of LGE were quantified with customized
software (MATLAB R2007b, Mathworks, Natick, Massa-
chusetts) with computer-assisted planimetry of short-axis im-
ages. With this method of LGE imaging, the minimum
detectable limit of LGE necrosis is a group of 10 hyperen-
hanced pixels—a voxel of 1.9  1.4  7 mm (12).
Laboratory markers. Plasma samples were obtained at
baseline and at 1, 6, 12, and 24 h after the procedure.
Samples were also stored in a81°C locked freezer. Cardiac
troponin I (cTnI) and CK-MB were quantified with auto-
mated chemiluminescent immunoassay techniques on the
Siemens ADVIA Centaur (cTnI-“Ultra” for the majority)
and Siemens IMMULITE, respectively (both Siemens
Healthcare Diagnostics, Frimley, United Kingdom). The
ADVIA Centaur cTnI-Ultra assay has a 10% imprecision at
0.05 g/l, with a 99th percentile URL of 0.06 g/l. The
MMULITE CK-MB assay has a 99th percentile URL of
.8 g/l, with 10% imprecision at this level.
Initial analyses were performed with the Siemens
ADVIA Centaur assay before the release of the new, highly
sensitive ADVIA Centaur cTnI-Ultra. To meet guideline
requirements of 10% imprecision at all reported biomar-
ker levels, re-analysis of frozen stored plasma samples with
the “Ultra” assay was performed when cTnI was0.20 g/l.
Detection of inflammatory markers with the Luminex
multiplex assay. Measurement of inflammatory markers
from frozen serum was performed with a multiplex assay
with Luminex xMAP technology (Luminex Corporation,
Austin, Texas). Tumor necrosis factor (TNF) alpha, myelo-
peroxidase (MPO), high-sensitivity C-reactive protein
(CRP), and serum amyloid A (SAA) were measured in
duplicate with Milliplex MAP kit (Millipore, Billerica,
Massachusetts). Intra- and inter-assay co-efficient of varia-
tion (CV) for all biomarkers were between 6% and 13%.
The peak value is defined as the maximum value reached in
the 24 h after PCI or, in the case of negative change, the
minimum value reached. The maximum change is defined
as the peak value minus the baseline value.
Electrocardiograms. The 12-lead electrocardiograms were
obtained before and after the PCI procedure and were
analyzed for the presence of new Q waves.
Definition of PMI groups. Patients were stratified into 3
groups with CK-MB: group 1: no injury (normal CK-MB);
group 2: PMN (CK-MB elevation between 1 and 3
99th percentile URL); group 3: MI type 4a (CK-MB 3
99th percentile). For comparison, we similarly defined the 3
universal definition cTnI groups: group 1 (no injury - no
elevation of cTnI), group 2 (PMN–cTnI elevated between
1 and 3 99th percentile URL); group 3 (MI type
4a–cTnI 3 99th percentile. Changes in CRP, SAA,
MPO, and TNF-alpha levels were compared between the
CK-MB– and troponin-defined groups. Additionally a
comparison was performed between patients with evidence
of CMR-LGE and those without.
Statistical analysis. Testing for normal distribution was
performed with the Kolmogorov-Smirnov test for normal-ity. Normally distributed variables are presented as mean 
SD unless stated otherwise. For comparisons between the 3
groups, we used 1-way analysis of variance for multiple
comparisons followed by Bonferroni post hoc correction.
Non-normally distributed variables are presented as median
(25th to 75th percentile), and for comparisons between
groups we used either the Kruskal-Wallis test (between 3
groups) or the Mann-Whitney U test (between 2 groups).
For categorical outcomes, chi square or Fisher exact test was
performed where appropriate. A probability of p 0.05 was
onsidered statistically significant. Receiver-operator char-
cteristic (ROC) curves were plotted to identify the optimal
iomarker cutoff point, which was defined as the point with
he shortest distance from point (0,1) (top left corner).
edCalc version 11.3 software (MedCalc Software, Maria-
erke, Belgium) and the DeLong et al. (24) method was
sed for the comparison of ROC curves. SPSS version 17.0
SPSS Inc., Chicago, Illinois) statistical package was used
or all other analyses.
esults
he PCI cohort of the MICASA study consisted of 40
atients, and a total of 32 were included in this analysis. Eight
atients were excluded from the study: 2 due to elevated
aseline cTnI, 1 had a pre-procedure upper respiratory infec-
ion with markedly raised baseline CRP of 75,000 ng/ml, 1
nderwent rotational atherectomy, and 4 had incomplete blood
ampling (Fig. 1).
The baseline characteristics of the patients are shown in
able 1. The mean age was 65 8.8 years in group 1, 58.3
.6 years in group 2, and 62.3 7.6 years in group 3 (p 
S). There was no evidence of difference in cardiovascular
Figure 1 Consort Statement
Flow Diagram of Patient Recruitment
CMR  cardiac magnetic resonance imaging;
CRP  C-reactive protein; PCI  percutaneous coronary intervention.
17
c
(
T
v
artery
656 Lim et al. JACC Vol. 57, No. 6, 2011
Biomarkers and Periprocedural Necrosis February 8, 2011:653–61risk factors and pattern of coronary artery disease between
the groups (Table 1).
There were no significant differences in baseline tro-
ponin, CK-MB, and inflammatory marker levels. The mean
number of implanted stents was significantly higher in
groups 2 and 3 compared with group 1: 5.2 1.9 and 5.0
.2 versus 3.5  1.7, p  0.03.
The procedure was uneventful in 27 (84%) patients.
Occlusive dissection was successfully treated in 3 patients,
and in 1 patient there was hemodynamic disturbance prob-
ably caused by distal embolization of plaque material. One
patient failed complete revascularization due to inability to
cross a chronic total occlusion and later underwent coronary
artery bypass grafting. Patients undergoing PCI received an
average of 4.3  1.8 stents, with an average stent length of
8.9  34.0 mm/patient. All patients received drug-eluting
stents: Taxus Express (44%) and Promus (19%) (Boston
Scientific, Natick, Massachusetts); Xience V (32%) (Abbott
Vascular, Redwood City, California); Cypher Select (5%)
(Cordis, Johnson and Johnson, Warren, New Jersey). Two
Baseline CharacteristicsTable 1 Baseline Characteristics
All Patients
(n  32)
Group 1: No Procedural Injury
CK-MB <99th Percentile
(<4.8 g/l)
(n  17)
Age, yrs 62.5 8.3 65.0 8.8
Unstable angina 6 (19%) 4 (26%)
Male 29 (91%) 14 (82%)
Prior MI 7 (22%) 5 (29%)
Diabetes 5 (16%) 5 (29%)
History of smoking 24 (75%) 13 (76%)
Current smoker 5 (16%) 3 (18%)
Family history of CAD 12 (38%) 7 (41%)
Hypertension 18 (56%) 12 (71%)
Hyperlipidemia 31 (97%) 17 (100%)
Disease pattern
LM or LM  1 vessel 3 (9%) 2 (12%)
LM  2 or 3 vessel 5 (16%) 4 (24%)
2 vessel 4 (13%) 2 (12%)
3 vessel 20 (63%) 9 (52%)
Lesions 3.1 1.1 3.3 1.2
SYNTAX score 23.2 6.9 23.1 8.1
Gensini score 40.7 19.7 42.5 18.8
Medications at enrollment
Aspirin 31 (97%) 16 (94%)
Clopidogrel 29 (91%) 15 (88%)
Statin 32 (100%) 17 (100%)
Beta-blocker 26 (81%) 12 (71%)
ACE inhibitor/ARB 14 (44%) 7 (41%)
Procedural characteristics
Abciximab use 23 (72%) 12 (71%)
Procedure time 67.5 26.3 63.1 22.2
Stents 4.3 1.8 3.5 1.7
Total stent length (mm) 78.9 33.7 67.1 34.6
Values are mean  SD or n (%). *p value for comparisons across the 3 groups.
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; CAD  coronarypatients also received a bare-metal stent each.Twenty-three (72%) patients received abciximab, and 21
of these patients also received a 12-h infusion after PCI.
Comparison of cTnI- and CK-MB–defined periprocedural
injury groups. Baseline CK-MB and cTnI values were not
significantly different among the 3 PMI groups (Table 2).
Figure 2 demonstrates the correlation between peak
CK-MB and peak cTnI (r2  0.79, p  0.001). A strong
orrelation was also present in patients without new LGE
n  27, r2  0.61, p  0.001).
Five of 32 patients (15%) had evidence of CMR-LGE.
he mean peak cTnI value in these patients was 13.4 g/l
ersus 0.93 g/l in patients without CMR-LGE (p 
0.001), and mean peak CK-MB value was 28.3 versus 4.7
g/l (p  0.001). All 5 patients with CMR-LGE fulfilled
the criteria for cTnI-defined MI type 4a. However when
using CK-MB–based definitions 2 of 5 patients with
CMR-LGE are categorized as PMN (group 2), and 3 of 5
patients have CK-MB–defined MI type 4a.
Comparison of the observed thresholds for PMN and MI
type 4a suggests that many more patients are categorized
roup 2: Periprocedural Necrosis
CK-MB >99th Percentile
(4.8–14.4 g/l)
(n  10)
Group 3: MI type 4a
CK-MB >3x 99th Percentile
(>14.4 g/l)
(n  5) p Value*
58.3 6.6 62.3 7.6 NS
2 (20%) 0 (0%) NS
10 (100%) 5 (100%) NS
0 (0%) 2 (40%) NS
0 (0%) 0 (0%) NS
7 (70%) 4 (80%) NS
2 (20%) 0 (0%) NS
3 (30%) 2 (40%) NS
3 (30%) 3 (60%) NS
10 (100%) 5 (100%) NS
1 (10%) 0 (0%) NS
1 (10%) 0 (0%) NS
0 (0%) 2 (40%) NS
8 (80%) 3 (60%) NS
3.0 0.9 2.8 0.8 NS
23.7 6.3 22.4 4.2 NS
43.7 23.1 28.4 12.8 NS
10 (100%) 5 (100%) NS
9 (90%) 5 (100%) NS
10 (100%) 5 (100%) NS
10 (100%) 4 (80%) NS
4 (40%) 3 (60%) NS
7 (70%) 4 (80%) NS
73.9 33.3 69.8 26.8 NS
5.2 1.9 5.0 1.2 0.03
91.7 30.5 93.4 25.7 NS
disease; CK-MB  creatine kinase-myocardial band; LM  left main; MI  myocardial infarction.Gwith MI type 4a with troponin than when the CK-MB
aneous
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for cTnI- and CK-MB–defined MI type 4a). Figure 3
compares the spectrum of patient distribution when the
PMI groups are defined with CK-MB (Fig. 3A) and cTnI
(Fig. 3B).
If grouping is performed with cTnI, 3 of 32 patients (9%)
have no evidence of PMI, 3 of 32 patients (9%) have PMN,
and 26 of 32 patients (82%) are considered to have MI type
4a. However, only 5 of those 26 patients had evidence of
Mean Biomarker Levels at Baseline and After PTable 2 Mean Biomarker Levels at Baseline
G1* No Injury
cTnI (g/l)
Baseline 0.06
1 h 0.06 (0.06–0.07) 0
6 h 0.08 (0.06–0.3) 0.3
12 h 0.3 (0.09–0.45) 1
24 h 0.12 (0.06–0.4) 1
CK-MB (g/l)
Baseline 1.7 (0.7–2.4) 1
1 h 1.8 (1.0–2.4) 1
6 h 2.1 (1.3–2.4) 3
12 h 2.1 (1.7–2.4) 6
24 h 2.3 (1.7–2.9) 6
Values are presented as median (interquartile range). *G1 to G3 re
periprocedural myocardial injury (PMI) groups.
cTnI  cardiac troponin I; MI  myocardial infarction; PCI  percut
Figure 2 Peak CK-MB and Troponin Values
Represented on a natural logarithmic scale. There was a strong correlation
(r2  0.79, p  0.001) between peak creatine kinase-myocardial band (CK-
MB) and cardiac troponin I (cTnI) values. G1 to G3 refer to CK-MB–defined
periprocedural myocardial injury (PMI) groups 1 to 3. Dashed blue lines repre-
sent the different thresholds for diagnosing myocardial infarction (MI) type 4a
when using CK-MB versus cTnI. Red symbols represents patients with late gad-
olinium enhancement (LGE) evidence of injury. A CK-MB definition closely
approximates LGE evidence of injury.CMR-LGE giving a positive predictive value of only 19%
and a poor specificity of 22% (Table 3).
When the CK-MB definition was applied, 17 of 32
patients (53%) had no evidence of injury, 10 of 32 patients
(32%) had PMN, and 5 of 32 patients (15%) were consid-
ered to have MI type 4a. In contrast, there was a high
specificity of 93% for CMR-LGE, and 3 of 5 patients
meeting MI type 4a criteria had new LGE giving a positive
predictive value of 60% (Table 3).
Inflammatory markers according to PMI groups. Pa-
tients with evidence of LGE on CMR had significantly
greater elevations of CRP (18.6 [11.0 to 45.1] mg/ml vs. 3.6
[1.7 to 8.5] mg/ml, p  0.01) and SAA (34.5 [11.4 to
239.0] mg/ml vs. 5.3 [2.3 to 16.8] mg/ml, p 0.05) but not
MPO (190 [34 to 549] ng/ml vs. 90 [22 to 210] ng/ml) or
TNF-alpha.(0.28 [0.36 to 6.1] pg/ml vs. 0.69 [0.18 to
2.6] pg/ml) compared with those without LGE.
Figure 4 demonstrates the changes of the 4 inflammatory
markers according to CK-MB– and cTnI-defined injury
groups. The percentage changes of both CRP and SAA
serum levels progressively increased across the CK-MB-
defined injury groups (p 0.05 for both) (Fig. 4). However,
the changes in serum levels of MPO and TNF-alpha across
the CK-MB–defined injury groups did not reach statistical
significance.
In contrast, there was no significant difference in the
levels of the examined inflammatory markers across the 3
cTnI-defined groups (Fig. 4). Therefore, the change in
inflammatory marker profiles reflect the differentiation of
injury made evident by measurement of CK-MB. No
differentiation in the magnitude of injury was evident when
troponin categorizations were used.
ROC analysis for biomarker detection of new CMR-LGE.
The ROC analysis for detection of CMR-LGE shows areas
under the curve of 0.985 (95% confidence interval: 0.864 to
1.000) for cTnI versus 0.970 (95% confidence interval:
0.840 to 0.999) for CK-MB, with no significant difference
After PCI
MN G3* MI Type 4a p Value
06 0.06 NS
6–0.8) 0.16 (0.1–1.0) 0.01
2–1.4) 3.2 (0.8–8.6) 0.01
–1.9) 5.4 (1.1–22.6) 0.01
–2.6) 6.3 (3.5–22.3) 0.01
–1.8) 1.1 (0.5–3.9) NS
–2.3) 3.2 (1.7–4.5) NS
–5.8) 13.9 (5.9–22.1) 0.01
–10.9) 26.7 (6.8–47.9) 0.01
–7.7) 21.0 (15.5–30.9) 0.01
reatine kinase-myocardial band (CK-MB)-defined universal definition
coronary intervention; PMN  periprocedural myocardial necrosis.CIand
G2* P
0.
.1 (0.0
5 (0.1
.3 (0.7
.3 (0.9
.3 (0.5
.5 (1.0
.3 (2.4
.0 (5.2
.6 (5.1
fer to cbetween the 2 areas (p  0.411). This indicates that cTnI is
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Biomarkers and Periprocedural Necrosis February 8, 2011:653–61not inferior to CK-MB for diagnosis of LGE necrosis;
however, at the current cutoff of 3 99th percentile URL
cTnI suffers from very poor specificity.
The optimal cTnI cutoff from ROC analysis of our data
would be a cTnI of 2.4 g/l (100% sensitivity, 93%
pecificity), which is 40 its 99th percentile URL of 0.06
g/l. The optimal cutoff for CK-MB is 9.5 g/l (100%
ensitivity, 93% specificity), which is double its 99th per-
entile URL of 4.8 g/l.
Our data demonstrate that cTnI and CK-MB have an
almost perfect linear correlation. Consequently both cTnI
and CK-MB can be used to detect periprocedural injury,
but the use of the current cutoff multipliers of the 99th
percentile result in differential results and categorization. By
altering the thresholds for cTnI, PMI group categorizations
similar to those described with CK-MB can be obtained.
For example, with our data, the equivalent thresholds for
cTnI would be:
G2: CK-MB–defined PMN: cTnI 0.8 g/l
(12 99th percentile URL)
G3: CK-MB–defined MI: type 4a cTnI 3.0 g/l
(50 99th percentile URL)
Figure 3 PMI Groups
According to (A) universal definition with cTnI as recommended biomarker, (B) un
cutoff for diagnosing periprocedural myocardial necrosis (PMN) and a 40 multipl
2-Way Contingency Tables for Biomarker Detection of CMR-LGETable 3 2-Way Contingency Tables for Biomarker Detection of
LGE 
cTnI-defined MI type 4a
MI type 4a  6
MI type 4a  21
Specificity  22% (6/27)
CK-MB–defined MI type 4a
MI type 4a  25
MI type 4a  2
Specificity  93% (2/27)CMR  cardiac magnetic resonance imaging; LGE  late gadolinium enhancement; other abbreviationsThe ideal definition thresholds. With a PMN cutoff
approximating that of CK-MB–defined PMN and an MI
Type 4a cutoff calculated from ROC analysis with CMR-
LGE injury, we can propose “ideal” cTnI cutoffs of 12
99th percentile (0.8 g/l) for PMN and 40 99th
ercentile (2.4 g/l) for MI type 4a. Figure 3C illustrates
he periprocedural injury group distribution of such a cTnI
efinition.
iscussion
his study confirms that a considerable number of patients
ndergoing complex PCI have elevation of biomarkers
espite a successful PCI procedure. Marked variation occurs
n proportions reaching universal definition arbitrary diag-
ostic levels for necrosis or infarction depending on whether
K-MB or troponin is measured. Our data suggest that,
ith this definition, CK-MB more readily differentiates
ecrosis and infarction than troponin. With CK-MB
lightly more than one-half of the patients have no evidence
f periprocedural injury, one-third of them have evidence of
eriprocedural necrosis, and roughly 15% can be classified as
I type 4a. Using troponin radically alters this distribution,
definition with CK-MB, (C) cTnI but with a 12 multiplier of 99th percentile
off for diagnosing MI type 4a. Abbreviations as in Figure 2.
-LGE
LGE 
0 Negative predictive value  100% (6/6)
5 Positive predictive value  19% (5/26)
ensitivity 100% (5/5)
2 Negative predictive value  93% (2/27)
3 Positive predictive value  60% (3/5)
Sensitivity  60% (3/5)iversal
ier cutCMR
Sas in Table 2.
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According to CK-MB- (left 4 panels) and cTnI-defined (right 4 panels) PMI groups. Median, interquartile range (box), and 5th to 95th percentile (whiskers).
MPO  myeloperoxidase; SAA  serum amyloid A; TNF  tumor necrosis factor; other abbreviations as in Figure 2.
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criteria for MI type 4a. However, redefining the troponin I
thresholds to 0.8 g/l (12 99th percentile) for necrosis
and 2.4 g/l (40 99th percentile) for MI type 4a allows a
comparable categorization to those identified by measure-
ment of post-procedural CK-MB.
Ten years ago, the CK-MB assay was regarded as the best
biomarker for detection of myocardial injury. The replace-
ment of CK-MB with troponin as the cardiac biomarker of
choice was primarily due to its superiority in acute coronary
syndrome risk stratification, because it was able to detect
patients that had experienced minor degrees of ischemia and
were at risk despite having CK-MB levels below the URL.
This was a consequence of the enhanced sensitivity and
specificity of troponin, resulting in improved differentiation
at low level, and also the higher population variability of
CK-MB levels, resulting in a higher absolute 99th percen-
tile CK-MB URL. Clinical experience with CK-MB ele-
vation after PCI demonstrated its ability to predict mortal-
ity, but troponin elevation (defined as99th percentile) was
not predictive (25). In this study by Cavallini et al. (25),
elevation of troponin occurred in almost 3 times as many
patients as CK-MB. Consequently it is likely that many
patients categorized with troponin elevation were in the
range 0.8 g/l, but their CK-MB was normal. This
ver-stringent categorization of troponin abnormality
ould result in significant dilution of any potential observed
ffect. Although it is clear that higher levels of troponin
levation after PCI accurately reflect new myocardial necro-
is, there has been persistent debate and concern about the
linical significance of lower levels of troponin elevation.
ost recently this concern has prompted prominent clinical
rial investigators to suggest avoiding the universal defini-
ion of periprocedural MI using troponin in favor of
K-MB, stating their concern over its impact on analysis
nd reporting of safety and efficacy data in stent trials
14,15).
Accurate differentiation between definitions of peripro-
edural necrosis and MI has practical and sociological
mplications as well as its implications for research. Lower-
ng the threshold for MI will increase the epidemiological
ncidence of MI and has significant psychological impact for
atients. The prospective inclusion of a heterogenous pa-
ient group with a different prognosis might potentially
onfound outcome trials of therapeutic strategies. In con-
rast, an accurate diagnosis of periprocedural necrosis has
ittle emotive implication and might more readily be ac-
epted as a benign procedural consequence.
In this study PCI patients with evidence of LGE on CMR
ave significant elevation of inflammatory markers compared with
hose patients with lesser biomarker abnormality and no evidence
f myocardial necrosis on CMR. Concerns that the current
hresholds for troponin might be oversensitive for stratification of
eriprocedural injury are supported by the results of the inflam-
atory cytokines in our study. It is known that myocardial injurynitiates an inflammatory cascade resulting in proportionate in-ammation, measurable by circulating markers (22). The inflam-
atory cytokines, especially CRP and SAA, demonstrate a
rogressive rise across the PMI groups when defined by CK-MB
Fig. 4). This step-wise progression was not evident when cTnI
as used to define injury groups (Fig. 4).
CRP is probably the best-studied inflammatory marker in
cute MI and PCI, and the proportionate rise of this marker
ith increasing CK-MB emphasizes its role. Serum amyloid
shares production in the liver and release kinetics character-
stics with CRP, and SAA elevation after tissue damage is
ell-established (26). Recent studies show that SAA is a
linically useful marker of inflammation, and its levels are
trongly associated with cardiovascular events (27). Myeloper-
xidase is a neutrophil activation marker, with circulatory levels
hat peak acutely at 1 to 3 h after PCI (28).
tudy limitations. Our study is limited by its small sample
ize.
The timing of biomarker samples (last time point at 24 h)
ight also have resulted in nonsignificant results for TNF-
lpha, which might demonstrate continual release kinetics
eyond 24 h.
onclusions
hen applying the current universal definition of MI to
eriprocedural injury, CK-MB should currently be the
referred biomarker. Under the current definition criteria,
roponin is oversensitive with the arbitrary limit of 3 99th
ercentile failing to discriminate between necrosis and MI
ype 4a. Redefining the troponin I thresholds for necrosis
nd MI type 4a will allow a more-standardized diagnostic
pproach to diagnosing PMI.
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